Core Insights - Alumis Inc. announced the acceptance of results from its Phase 3 ONWARD program for envudeucitinib, a TYK2 inhibitor for moderate-to-severe plaque psoriasis, for a late-breaking oral presentation at the 2026 AAD Annual Meeting [1][2] - A new biomarker analysis from the Phase 2 STRIDE trial of envudeucitinib will also be presented as an e-poster at the same event [1][2] Presentation Details - The late-breaking oral presentation will cover the 24-week results from the randomized, double-blind, active comparator- and placebo-controlled Phase 3 ONWARD 1 and 2 studies, scheduled for March 28, 2026, at 11:12 am MDT [2] - The e-poster will focus on how envudeucitinib attenuates inflammatory biomarkers in plaque psoriasis, based on a subgroup analysis from the STRIDE Phase 2 clinical trial [2] Investor Engagement - Alumis will host a webcast for investors on March 29, 2026, at 5:00 pm MDT to review the Phase 3 ONWARD data presented at AAD, with a replay available on the company's website [3] Product Overview - Envudeucitinib is a next-generation, highly selective oral allosteric inhibitor of TYK2, designed to address immune dysregulation in diseases driven by proinflammatory mediators [4] - The drug has shown sustained, maximal 24-hour inhibition in psoriasis patients while minimizing off-target effects [4] - Alumis is also evaluating envudeucitinib in the Phase 3 ONWARD3 program and in a Phase 2b trial for systemic lupus erythematosus, with topline data expected in Q3 2026 [4] Company Background - Alumis is a late-stage biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases, leveraging a proprietary data analytics platform [5] - The company's pipeline includes envudeucitinib for moderate-to-severe plaque psoriasis and systemic lupus erythematosus, as well as A-005 for neuroinflammatory diseases and lonigutamab for thyroid eye disease [5]

Company Overview - Alumis Inc. is a late-stage biopharma company focused on developing next-generation targeted therapies for immune-mediated diseases [2] - The company utilizes a proprietary data analytics platform and precision approach to enhance patient health and outcomes [2] Product Pipeline - Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, including envudeucitinib (formerly ESK-001), aimed at treating systemic immune-mediated disorders such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus [2] - The pipeline also features A-005 for neuroinflammatory and neurodegenerative diseases, and lonigutamab, a subcutaneously delivered therapy for thyroid eye disease [2] - Several preclinical programs have been identified through the company's precision approach [2] Investor Engagement - Alumis will participate in multiple investor conferences, including the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026, and the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026 [4] - Live webcasts of these events will be accessible on the company's website, with replays archived for 90 days [1][4]

Core Insights - Alumis Inc. is set to report topline data from the Phase 3 ONWARD clinical program for envudeucitinib in patients with moderate-to-severe plaque psoriasis on January 6, 2026 [1] - A conference call and webcast will be held on the same day at 8:00 a.m. ET to discuss the results [2] Company Overview - Alumis is a late-stage biopharma company focused on developing next-generation targeted therapies for immune-mediated diseases [3] - The company is leveraging a proprietary data analytics platform to develop a pipeline of oral tyrosine kinase 2 inhibitors, including envudeucitinib for systemic immune-mediated disorders and A-005 for neuroinflammatory diseases [3] - The pipeline also includes lonigutamab for thyroid eye disease and several preclinical programs identified through a precision approach [3]

Core Insights - Defence Therapeutics Inc. will present new scientific data on its Accum® technology at the World ADC Conference in San Diego, highlighting its potential to enhance the efficacy of antibody-drug conjugates (ADCs) [1][2] Company Overview - Defence Therapeutics is a biotechnology company focused on drug delivery technologies, specifically developing next-generation ADC products using its proprietary Accum® platform [5] - The Accum® technology is designed to improve intracellular delivery and endosomal escape of therapeutic payloads, addressing limitations of current ADCs and enabling higher potency with reduced off-target toxicity [2][5] Scientific Findings - New results to be presented at the conference demonstrate Accum®'s ability to significantly improve the therapeutic index of ADCs, allowing for more efficient delivery of toxic payloads directly into cancer cells [2][3] - The Chief Scientific Officer of Defence Therapeutics expressed excitement about sharing these findings with the scientific community and advancing research towards next-generation targeted therapies [3] Conference Details - The World ADC Conference is a premier event for ADC innovation, featuring 1,400 industry attendees and over 170 world-class speakers, providing significant networking opportunities [4]